[HTML][HTML] Wnt signaling in colorectal cancer: pathogenic role and therapeutic target

H Zhao, T Ming, S Tang, S Ren, H Yang, M Liu, Q Tao… - Molecular cancer, 2022 - Springer
Abstract Background The Wnt signaling pathway is a complex network of protein interactions
that functions most commonly in embryonic development and cancer, but is also involved in …

[HTML][HTML] Biomarkers in colorectal cancer: current research and future prospects

OO Ogunwobi, F Mahmood, A Akingboye - International journal of …, 2020 - mdpi.com
Colorectal cancer (CRC) is a leading cause of death worldwide, despite progress made in
detection and management through surgery, chemotherapy, radiotherapy, and …

Patient-derived tumour xenografts as models for oncology drug development

JJ Tentler, AC Tan, CD Weekes, A Jimeno… - Nature reviews Clinical …, 2012 - nature.com
Progress in oncology drug development has been hampered by a lack of preclinical models
that reliably predict clinical activity of novel compounds in cancer patients. In an effort to …

[HTML][HTML] Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health

WH Chappell, LS Steelman, JM Long, RC Kempf… - Oncotarget, 2011 - ncbi.nlm.nih.gov
Abstract The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by
genetic alterations in upstream signaling molecules such as receptor tyrosine kinases …

One mouse, one patient paradigm: New avatars of personalized cancer therapy

P Malaney, SV Nicosia, V Davé - Cancer letters, 2014 - Elsevier
Over the last few decades, study of cancer in mouse models has gained popularity.
Sophisticated genetic manipulation technologies and commercialization of these murine …

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents

M Mao, F Tian, JM Mariadason, CC Tsao… - Clinical cancer …, 2013 - AACR
Purpose: Vemurafenib, a selective inhibitor of BRAFV600, has shown significant activity in
BRAFV600 melanoma but not in less than 10% of metastatic BRAFV600 colorectal cancers …

[HTML][HTML] Biology of colorectal cancer

F Arvelo, F Sojo, C Cotte - Ecancermedicalscience, 2015 - ncbi.nlm.nih.gov
Colorectal cancer is a serious health problem, a challenge for research, and a model for
studying the molecular mechanisms involved in its development. According to its incidence …

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

CD Britten - Cancer chemotherapy and pharmacology, 2013 - Springer
Abstract The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are two of the most
frequently dysregulated kinase cascades in human cancer. Molecular alterations in these …

[HTML][HTML] Systematic review of patient-derived xenograft models for preclinical studies of anti-cancer drugs in solid tumors

Y Koga, A Ochiai - Cells, 2019 - mdpi.com
Patient-derived xenograft (PDX) models are used as powerful tools for understanding
cancer biology in PDX clinical trials and co-clinical trials. In this systematic review, we focus …

[HTML][HTML] Zebrafish avatars towards personalized medicine—a comparative review between avatar models

B Costa, MF Estrada, RV Mendes, R Fior - Cells, 2020 - mdpi.com
Cancer frequency and prevalence have been increasing in the past decades, with
devastating impacts on patients and their families. Despite the great advances in targeted …